SWOG clinical trial number
SWOG-9124

Evaluation of Edatrexate (EDX) in Patients with Relapsed or Refractory Germ Cell Tumors, Phase II

Closed
Phase
Accrual
62%
Published
Abbreviated Title
Testicular
Activated
06/01/1992
Closed
09/01/1996

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1999

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG-9124).

FJ Meyers;D Lew;PN Lara;S Williamson;E Marshall;SP Balcerzak;SE Rivkin;W Samlowski;ED Crawford Investigational New Drugs 16:347-351

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/EA8185